Stock DEST DESTINY PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Destiny Pharma plc

Equities

DEST

GB00BDHSP575

Delayed London S.E.
Other stock markets
 02:59:59 2024-07-03 am EDT 		5-day change 1st Jan Change
8.65 GBX 0.00% Intraday chart for Destiny Pharma plc -11.28% -87.64%
Jun. 18 Destiny Pharma presents "exciting" data for ringworm drug AN
Jun. 12 EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10 AN

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Destiny Pharma presents "exciting" data for ringworm drug
AN
Destiny Pharma : Result of 2024 Annual General Meeting
PU
EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10
AN
EARNINGS AND TRADING: Chariot loss narrows; Destiny Pharma approval
AN
Destiny Pharma Wins UK Regulator's Innovation Passport Tag for Nasal Drug Candidate
MT
Destiny Pharma plc Receives Innovation Passport Designation by the UK MHRA for XF-73 Nasal for the Prevention of Post-Surgical Site Infections
CI
Destiny Pharma : Notice of 2024 Annual General Meeting
PU
Norcros sells Johnson Tiles UK; Trifast trading well
AN
Transcript : Destiny Pharma plc, 2023 Earnings Call, Apr 25, 2024
AIM WINNERS & LOSERS: Kromek jumps 14% on US government contract
AN
Destiny Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
EARNINGS AND TRADING: STV raises holding in Two Cities Television
AN
Destiny Pharma to Advance Skin, Colon Infection Therapies After Positive Evaluations
MT
Destiny Pharma plc Announces Clinical Development Update Positive Results from XF-73 Dermal Safety Study
CI
Destiny Pharma seeks to capitalise on XF-73 market potential in 2024
AN
Destiny Pharma Says Talks Ongoing with Potential Partners for Nasal Asset
MT
Destiny Pharma celebrates study findings on "potent" flagship drug
AN
AIM WINNERS & LOSERS: Destiny Pharma posts "landmark" XF-73 data
AN
Destiny Pharma plc Announces the Publication of New Microbiological Data on Xf-73 (Exeporfinium Chloride), Its Leading Antibacterial Drug,In Frontiers in Cellular and Infection Microbiology
CI
Dianomi swings to loss; Epwin revenue up
AN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DEST Stock
  4. News Destiny Pharma plc